Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cloudflare Inc (NET) vs Novavax Inc (NVAX) Price & Performance

Cloudflare IncTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Cloudflare Inc vs Novavax Inc — how do they compare? Cloudflare Inc trades at $315.14 (market cap $101.23B), while Novavax Inc trades at $9.88 (market cap $1.68B). The key difference: Cloudflare Inc is far larger — about 60.3× Novavax Inc's market cap, and Cloudflare Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

NETNVAX
Market Cap
$101.23B$1.68B
Sector
TechnologyHealth
52-Week High
$330.74$11.19
52-Week Low
$160.16$6.22
Enterprise Value
$100.60B$1.26B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cloudflare Inc

Cloudflare (NET) trades at $284.41, up 1.97% with strong analyst support (72.5% buy ratings) and a $342.74 consensus price target. Recent partnerships with OpenAI and AI security innovations drive momentum, though negative net margins and premium valuations (P/S 39.82) pose challenges. Technical indicators show neutral signals with support at $275 and resistance at $292.

Outlook remains growth-focused with AI-driven revenue potential, but profitability concerns and high valuation multiples require careful monitoring. The stock offers upside from analyst targets but faces execution risks in competitive cybersecurity markets.

Novavax Inc

Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.

The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cloudflare Inc

Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.

Read more on NET

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX